Thus, targeting KIT activity has been a focus of pharmacological strategies to treat aggressive SM, with the limitation that the extended tyrosine kinase conformation of D816V-KIT is not inhibited by tyrosine kinase inhibitors such as imatinib (21, 23). Here, KIT is linked to systemic mastocytosis.